Dapagliflozin Linked to Consistent Reductions in CV and Kidney Outcomes in T2D - The Cardiology Advisor

A study was conducted to determine the efficacy and safety of dapagliflozin when taken with CV medications in patients with type 2 diabetes and HF, kidney disease, or both.

Treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin has demonstrated consistent reductions in risk for cardiovascular (CV) death/ hospitalization for heart failure (HF) … [+4325 chars]

full article...